Ardelyx Revenue and Competitors

Location

#4720

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Ardelyx's estimated annual revenue is currently $24.6M per year.(i)
  • Ardelyx's estimated revenue per employee is $155,981
  • Ardelyx's total funding is $326.4M.

Employee Data

  • Ardelyx has 158 Employees.(i)
  • Ardelyx grew their employee count by 13% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

Ardelyx is focused on enhancing the way people with kidney and cardiovascular diseases are treated by developing innovative first-in-class medicines. Ardelyx's pipeline includes tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, for which the Company is preparing for NDA filing mid-year, and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELAᅢᆵᅥメᅡᄁ (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin Corporation in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories. For more information, please visit http://www.ardelyx.com/ and connect with us on Twitter @Ardelyx.

keywords:Biotechnology

$326.4M

Total Funding

158

Number of Employees

$24.6M

Revenue (est)

13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Ardelyx News

2022-04-17 - Ardelyx, Inc. (NASDAQ:ARDX) Given Consensus Rating of ...

Ardelyx logo Ardelyx, Inc. (NASDAQ:ARDX – Get Rating) has received a consensus recommendation of “Buy” from the nine ratings firms that are...

2022-04-06 - Ardelyx and Kyowa Kirin Amend License Agreement for ...

WALTHAM, Mass., April 11, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover,...

2022-03-30 - Ardelyx Announces US Launch of IBSRELA®, a New First-in ...

Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet...

2021-09-03 - Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial

FREMONT, Calif. and WALTHAM, Mass., Sept. 3, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.3M158-2%N/A
#2
$17.7M1615%N/A
#3
$48.1M16237%N/A
#4
$26.2M1644%N/A
#5
$26.3M1653%N/A